Lantheus Holdings, Inc. $LNTH Shares Sold by Focus Partners Wealth

Key Points

• Focus Partners Wealth reduced its stake in Lantheus Holdings by 6.5%, now owning 83,450 shares valued at approximately $8.1 million after selling 5,833 shares in the first quarter.
• Analysts have issued varying price targets for Lantheus, with an average target of $91.60 following recent adjustments, while four analysts rated the stock as a "Buy."
• Insiders sold a total of 6.8 million shares valued at $382.4 million over the last 90 days, impacting the company's ownership structure where insiders now hold only 1.5% of shares.

Focus Partners Wealth reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 6.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,450 shares of the medical equipment provider's stock after selling 5,833 shares during the period. Focus Partners Wealth owned approximately 0.12% of Lantheus worth $8,145,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in LNTH. State of Michigan Retirement System boosted its holdings in Lantheus by 0.6% in the 1st quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider's stock worth $1,620,000 after acquiring an additional 100 shares during the period. Signaturefd LLC lifted its position in shares of Lantheus by 36.5% during the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 116 shares in the last quarter. Intrust Bank NA boosted its stake in shares of Lantheus by 2.9% in the first quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider's stock valued at $431,000 after purchasing an additional 125 shares during the period. Nisa Investment Advisors LLC grew its holdings in Lantheus by 2.1% during the 1st quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider's stock valued at $653,000 after purchasing an additional 139 shares in the last quarter. Finally, Moody National Bank Trust Division increased its stake in Lantheus by 1.0% during the 1st quarter. Moody National Bank Trust Division now owns 14,910 shares of the medical equipment provider's stock worth $1,455,000 after buying an additional 141 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Truist Financial set a $63.00 price target on shares of Lantheus and gave the stock a "hold" rating in a research note on Monday, August 11th. Mizuho dropped their target price on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th. JMP Securities reduced their price target on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 7th. B. Riley decreased their price target on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd. Finally, William Blair restated a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. Four research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $91.60.

Insider Transactions at Lantheus

In other Lantheus news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the business's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares of the company's stock, valued at $195,246,296.05. The trade was a 49.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares of the company's stock, valued at $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,812,000 shares of company stock valued at $382,427,380 over the last ninety days. Company insiders own 1.50% of the company's stock.

Lantheus Stock Down 3.7%

Shares of LNTH stock opened at $52.94 on Friday. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $118.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. The business's fifty day moving average is $63.98 and its 200-day moving average is $81.27. The stock has a market cap of $3.60 billion, a PE ratio of 14.08 and a beta of 0.15.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The company had revenue of $378.05 million for the quarter, compared to analyst estimates of $389.69 million. During the same period last year, the firm earned $1.80 earnings per share. The firm's revenue for the quarter was down 4.1% on a year-over-year basis. Equities analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.